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The surface glycoproteins of viruses can play important roles in viral attachment, entry, and morphogenesis. Here, we
investigated the role of the attachment G glycoprotein of human respiratory syncytial virus (RSV) in viral infection. RSV G is
produced both as a complete, transmembrane form and as an N-terminally truncated form that is secreted. Using reverse
genetics, we created mutant recombinant RSVs (rRSV) that do not express G (DG) or express either the secreted or the
membrane-bound form of G only (sG and mG, respectively). In Vero cells, the DG virus formed plaques and grew as efficiently
as wild-type rRSV and mG. In contrast, DG replicated less efficiently and did not form distinct plaques in HEp-2 cells. This
defect was primarily at the level of the initiation of infection, with only a minor additional effect at the level of packaging.
Replication of DG in the respiratory tract of mice was very highly restricted, indicating that G is important in vivo. Although
the G protein expressed by the sG virus was confirmed to be secreted, this virus grew at least as efficiently as wild-type in
HEp-2 cells and was only moderately attenuated in vivo. Thus, the G protein was important for efficient replication in HEp-2
cells and in vivo, but this function could be supplied in large part by the secreted form and thus does not require the
cytoplasmic and transmembrane domains. Amino acids 184–198 have been identified as the major heparin-binding domain
of the G protein and were implicated in mediating binding to cells [S. A. Feldman et al., 1999, J. Virol. 73, 6610–6617].
Heparin-like glycosaminoglycans also appeared to be important for infection in vitro by direct clinical isolates of RSV. Deletion
of amino acids 187–197 from rRSV did not reduce its sensitivity to neutralization in vitro by incubation with soluble heparin,
did not reduce its efficiency of growth in vitro, and resulted in only a modest reduction in vivo. Thus, the putative
heparin-binding domain is not the sole determinant of heparin sensitivity and is not a critical functional domain.
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Human respiratory syncytial virus (RSV), the prototype
pneumovirus, is one of the most important etiologic
agents of pediatric respiratory disease worldwide (Col-
lins et al., 2001). Its genome consists of a single, nega-
tive-sense RNA of 15,222 nucleotides (for strain A2) en-
coding 10 major subgenomic mRNAs and 11 viral pro-
teins. Three of these proteins form the minimum viral
polymerase: the N nucleocapsid protein, P phosphopro-
tein, and large L polymerase subunit. The 22-kDa M2-1
protein encoded by the 59-proximal open reading frame
(ORF) of the M2 mRNA has been shown to be a tran-
scription antitermination factor and likely is associated
with the viral nucleocapsid (Collins et al., 1996; Fearns
and Collins, 1999; Garcia et al., 1993; Hardy and Wertz,
1998). There are three transmembrane surface glycopro-
teins: the G glycoprotein that had been identified as
mediating viral attachment (Levine et al., 1987); the fu-
sion F glycoprotein that mediates viral penetration; and
the small SH protein that is of unknown function but can
be deleted with little effect on virus replication in vitro or
in vivo (Bukreyev et al., 1997; Whitehead et al., 1999). Thet
e
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283and F glycoproteins are the major RSV neutralization
nd protective antigens. The matrix M protein is a non-
lycosylated internal virion protein that is important in
irion morphogenesis (Teng and Collins, 1998). There are
wo nonstructural proteins, NS1 and NS2, that enhance
irus growth in vitro and in vivo but are not essential and
an be deleted singly or in combination (Schlender et al.,
000; Teng and Collins, 1999; Teng et al., 2000; White-
ead et al., 1999). Recent results with bovine RSV indi-
ate that both proteins serve as antagonists of the type
interferon-mediated antiviral state (Schlender et al.,
000). The RSV M2 mRNA also contains a second ORF
hat encodes the M2-2 protein, which appears to down-
egulate transcription and up-regulate RNA replication
Bermingham and Collins, 1999; Jin et al., 2000).
The RSV G protein is a highly glycosylated type II
ransmembrane protein containing an N-terminal cyto-
lasmic domain (amino acids 1–37), a noncleaved hydro-
hobic signal/anchor (amino acids 38–63), and an
ctodomain (amino acids 64–298; amino acid numbering
ased on strain A2) that mostly consists of two mucin-
ike domains rich in serine, threonine, and proline and
eavily glycosylated with N- and O-linked sugars. The
umber of N-linked carbohydrate chains can vary be-ween different strains of RSV, from four in A2 strain to
ight in Long strain, and there are more than 70 potential
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284 TENG, WHITEHEAD, AND COLLINSacceptor sites for O-linked sugars that are not highly
conserved between strains (Collins et al., 2001). Fully
glycosylated G migrates in gel electrophoresis as a
broad band of Mr of 84–90 kDa, compared to an Mr of 33
Da for the unglycosylated precursor. The mucin-like
omains are separated by a stretch of 13 amino acids
hat is exactly conserved between different strains and
ubgroups of RSV. This conserved domain overlaps with
our closely spaced, conserved cysteine residues that
ppear to form a cystine noose (Johnson et al., 1987;
Langedijk et al., 1998).
The G protein also is produced as an N-terminally
truncated form that is secreted from infected cells (Hen-
dricks et al., 1988). Secreted G is synthesized by alter-
native translational initiation at the second methionine
(codon 48) of the G ORF (Roberts et al., 1994). This
primary translation product would contain a partial sig-
nal/anchor (amino acids 48–63) that apparently mediates
translocation into the exocytic pathway. The protein is
subsequently trimmed proteolytically to remove the N-
terminal 65 or 74 amino acids, thereby completely remov-
ing the cytoplasmic and transmembrane domains (Hen-
dricks et al., 1988; Roberts et al., 1994). It is estimated
that the soluble form accounts for approximately 16–20%
of the total G protein synthesized in RSV-infected cell
culture, but accounts for approximately 80% of the G
protein released into the medium by 24 h postinfection
(Hendricks et al., 1988).
The RSV G protein was identified as the RSV attach-
ment protein based on the ability of G-specific antibodies
to inhibit the binding of radiolabeled RSV to cultured
cells, whereas antibodies specific to F did not block
binding (Levine et al., 1987). More recently, however, this
identification was brought into question because the
RSV subgroup B cp-52 virus, a biologically derived vac-
cine candidate, was found to have sustained a sponta-
neous deletion of the SH and G genes (Karron et al.,
1997). In another study, F and M were essential for the
production and passage of virus-like particles in a mini-
genome packaging system, whereas G was not, al-
though the inclusion of G increased the efficiency 10-fold
(Teng and Collins, 1998).
Although the cellular receptor for RSV has not been
identified, recent studies provided evidence that the cell
surface glycosaminoglycans (GAGs) heparan sulfate and
chondroitin sulfate B are important for efficient infection
by RSV in vitro, perhaps representing an initial step in
attachment (Feldman et al., 1999; Hallak et al., 2000a,b;
Krusat and Streckert, 1997). RSV infectivity can be re-
duced by preincubation of virus with soluble forms of
these or related GAGs, or by their depletion from the cell
surface by enzymatic treatment or cellular mutation. The
G protein was found to bind specifically to immobilized
heparin, and further studies with linear peptides identi-
fied amino acids 184–198 as the major heparin-binding
domain (HBD) of G (Feldman et al., 1999; Krusat andStreckert, 1997). The putative HBD overlaps with the
downstream end of the cysteine-rich region mentioned
above. More recently, the abovementioned cp-52 virus,
having F as the sole transmembrane viral glycoprotein,
was shown to be sensitive to neutralization in vitro by
heparin, and F protein also was shown to bind to immo-
bilized heparin (Feldman et al., 2000).
In the present study, we used reverse genetics to
construct recombinant RSV (rRSV), in which the G gene
was deleted altogether (DG virus), or in which the G gene
was modified to express only the membrane-anchored or
secreted form (mG and sG viruses, respectively). In ad-
dition, we made two different viruses in which the puta-
tive HBD of the G protein was deleted (HBD-wt and
HBD-mut viruses) and also ablated an upstream AUG
which overlaps the G gene start signal (Ggs virus) to
investigate its effect on expression. These viruses were
compared with wild-type (wt) RSV with regard to depen-
dence on cellular GAGs and for replication in vitro and in
the respiratory tract of BALB/c mice.
RESULTS
Construction of antigenomic cDNAs with a mutant or
deleted G gene
To examine the role of the G protein in RSV replication,
we introduced a series of mutations into a cDNA clone of
the antigenome of the wt rRSV strain A2 (rA2, Fig. 1).
First, we deleted the entire G gene to create mutant DG
(Fig. 1a). The resulting genome would be 950 nt shorter
than that of wt RSV (14,273 vs 15,223 nt) and would
encode only nine mRNAs. The newly made SH-F inter-
genic would be 69 nt, longer than natural RSV intergenic
regions, but similar to that of the previously described
DSH virus (Bukreyev et al., 1997). Furthermore, we re-
cently showed that the length of an RSV intergenic region
can be increased to 100 nt or more with no detectable
effect on virus replication in vitro or in vivo (Bukreyev et
al., 2000).
The ORF encoding the complete, 298 amino acid RSV
G protein initiates with the second AUG of the mRNA (nt
4689–4691 in the complete antigenome sequence, see
Fig. 1a). The first AUG of the mRNA (antigenome nt
4681–4683) lies 8 nt upstream of the G ORF and is
contained within the 10-nt transcription gene-start signal.
This AUG opens a short, 15-codon ORF that overlaps the
G ORF and has the potential to down-regulate G expres-
sion by diverting ribosomes. The third AUG in the G
mRNA (antigenome nt 4830–4832) constitutes codon 48
in the G ORF: initiation at this site, followed by N-terminal
proteolytic trimming of the translation product, results in
the secreted form of the G protein (Roberts et al., 1994).
To examine the contributions of these structural features,
285RSV G MUTANT VIRUSESwe mutated each one in turn. The first AUG in the mRNA
was mutated to AUC to block possible expression of its
15-codon ORF, creating mutant Ggs. The second AUG in
the mRNA, encoding Met-1 of the G protein, was elimi-
nated by deleting nucleotides 4689–4829, a 141-nt seg-
ment containing the coding sequence for the cytoplas-
FIG. 1. (a) Construction of rRSV antigenomic cDNAs in which the G
of rRSV, flanked by naturally occurring PacI and BamHI sites, was m
4681–4683) that occurs before the G ORF and initiates the short ORF th
cytoplasmic domains of G by fusing the 59 untranslated region of the G
form (sG); mutate codon Met-48 (nt 4830–4832) to Ile-48, which ablates
The sequence of wt rRSV (rA2) is shown for comparison. Numbers refer
are italicized; transcription signals are underlined; deletions are indicate
mutated residues are in lowercase. GS, gene start; GE, gene end; IG,
the G protein. Amino acids 170–205 of wt G protein are shown at the top
was created by deleting the coding sequence for 11 amino acids (K-18
11 amino acid deletion together with substitution of alanine in place of
acid positions in the full-length membrane-bound form of G.mic and part of the transmembrane domains of G. This
mutation replaced the Met-1 codon with that of Met-48,resulting in a truncated G ORF that would encode only
the secreted form of G, creating mutant sG. The third
AUG in the mRNA, encoding Met-48 of the G protein, was
changed to AUU (Ile-48), abolishing synthesis of the
secreted form of G so that the ORF would encode only
the complete transmembrane form (mutant mG). Addi-
as mutated or deleted. A plasmid containing the G, F, and M2 genes
to delete the G gene in its entirety (DG); ablate an AUG codon (nt
laps the beginning of the G ORF (Ggs); delete the transmembrane and
to codon Met-48, so that expression of G would yield only the secreted
is of secreted G in favor of the complete transmembrane protein (mG).
otide positions in the recombinant antigenomic cDNA; restriction sites
verted triangles; methionine codons and mutant derivatives are in bold;
nic region. (b) Deletion of a putative heparin-binding domain (HBD) in
e putative HBD (amino acids 184–198) is boxed. One mutant, G HBD-wt,
197). A second mutant, G HBD-mut, was created containing the same
ne at positions 198, 199, and 200 (underlined). Numbers denote aminogene w
odified
at over
mRNA
synthes
to nucle
d by in
interge
, and th
7 to K-
threonitional mutants containing changes in the putative HBD of
G (Fig. 1b) are described later.
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286 TENG, WHITEHEAD, AND COLLINSRecovery of rRSVs with mutant or deleted G genes
Recombinant viruses were recovered from the various
mutant antigenomic cDNAs by cotransfection with N, P,
M2-1, and L support plasmids and coinfection with
MVA-T7 vaccinia virus, as described (Collins et al., 1995).
The mutant G viruses were all readily recovered; how-
ever, the DG virus did not grow efficiently in HEp-2 cells.
This result was confirmed with virus recovered from a
second, independent DG antigenomic cDNA (data not
shown), indicating that the poor growth likely was not
due to an adventitious mutation elsewhere in the ge-
nome. However, the DG virus was found to grow as
efficiently as wt RSV in Vero cells. This comparison is
shown in Fig. 2: whether inoculated at an m.o.i. of 0.1 or
0.01 PFU/cell, growth of the DG virus was equivalent to
that of wt rA2 in Vero cells (Figs. 2c and 2d) but was
reduced 103- or 104-fold in HEp-2 cells (Figs. 2a and 2b).
Interestingly, the sG virus, encoding only secreted G,
grew similarly to rA2 in both Vero and HEp-2 cells;
indeed, it was marginally more efficient in multicycle
growth (Figs. 2c and 2d). The mG virus, expressing only
FIG. 2. Growth of G mutant rRSVs in HEp-2 and Vero cells. Duplicat
(a, c) or 0.01 (b, d) PFU/cell with mutant or wt rRSVs, as indicated. Supe
assay on Vero cells under methyl cellulose. Plaques were visualized b
mean titers (log10 PFU/ml) are shown.transmembrane G, was very similar in growth efficiency
to wt rA2. Similarly, the Ggs virus, in which the AUG of the
aupstream 15-codon ORF was substituted, replicated with
the same efficiency as rA2 (Fig. 2).
When analyzed by plaque assay (Murphy et al., 1990),
all of the mutant G viruses formed visible plaques in Vero
cells (Table 1), although those of the DG virus were
slightly smaller than for the other viruses. In HEp-2 cells,
res of HEp-2 (a, b) or Vero (c, d) cells were infected at an m.o.i. of 0.1
ts were harvested at the indicated time points and analyzed by plaque
nostaining with RSV-specific antibodies (Murphy et al., 1990), and the
TABLE 1
Cell Line Dependence of Plaque Formation
by Recombinant RSV Lacking G
Virus
Virus titers (log PFU/ml)a
HEp-2 Vero
rA2 7.2 7.4
Ggs 6.5 6.4
DG ,0.7b 6.2
sG 6.4 6.3
mG 6.4 6.5
G HBD-wt 6.0 6.1
G HBD-mut 6.1 6.1
a Viruses were grown in Vero cells and then titered on monolayers of
ither HEp-2 or Vero cells as described (Murphy et al., 1990). Showne cultu
rnatanre the means of two independent experiments.
b In HEp-2 cells, the DG virus formed foci that were indistinct.
incub
287RSV G MUTANT VIRUSESDG did not form distinct plaques after 6 days under
methyl cellulose, although diffuse foci of infected cells
could be distinguished by immunostaining. In contrast,
all the other viruses formed distinct plaques (Table 1).
The inability of the DG virus to form distinct plaques in
HEp-2 cells was confirmed with virus rescued from
an independent DG antigenomic cDNA (data not
shown). For all of the other viruses, the efficiency of
plaque formation in HEp-2 or Vero cells was essentially
identical.
The cytopathology associated with each virus was
compared by infecting HEp-2 or Vero cell monolayers
at an m.o.i. of 0.3 PFU/cell with each virus, followed
by incubation under methyl cellulose for 4 days. As
shown in Fig. 3, wt rA2 (b) and the Ggs virus (c) formed
large syncytia in HEp-2 cells. In comparison, the syncytia
associated with the mG virus (f) in HEp-2 cells were
somewhat larger while those formed by sG (e) were
somewhat smaller. The DG virus (Fig. 3d) did not form
distinct syncytia in HEp-2 cells. In Vero cells, infection by
rA2, Ggs, and mG resulted in the formation of foci of
fused cells (Figs. 3h, 3i, 3l, respectively). Vero cells in-
fected by DG (Fig. 3j) showed areas of rounded cells but
did not form visible syncytia. Interestingly, infection with
sG (Fig. 3k) resulted in the formation of syncytia that
were more prominent that those formed in this cell type
by wt rA2. As described in the next section, cells infec-
ted with the sG virus did not contain detectable cell-
associated G protein, indicating that syncytium formation
FIG. 3. Photomicrographs of HEp-2 or Vero cells infected by G muta
infected with wt rA2 (b, h), Ggs (c, i), DG (d, j), sG (e, k), or mG (f, l) and
at a magnification of 103.by RSV does not require efficient expression of cell-
surface G.Viral RNA and protein synthesis by G mutant rRSVs
To confirm the presence of the engineered mutations
in the recombinant viruses, Vero cells were infected with
each mutant virus and, 48 h postinfection, total intracel-
lular RNA was isolated and analyzed by Northern blot
hybridization. Hybridization with a probe for the G mRNA
confirmed that the DG virus did not express G mRNA
(Fig. 4a, lane 4). The G mRNA from cells infected with sG
displayed increased mobility compared to that of wt rA2,
consistent with deletion of the 141-nt segment encoding
the transmembrane and cytoplasmic domains of G (Fig.
4a, lane 5). Hybridization with an N-specific probe con-
firmed the expression of other viral mRNAs (Fig. 4b).
To analyze protein expression, Vero cells were in-
fected with the various mutant rRSVs, and the cells were
harvested 48 h later and subjected to Western blot anal-
ysis. Analysis with a rabbit antiserum raised against
purified RSV detected the major RSV structural proteins
N, P, M, and M2-1 in all infected-cell extracts (Fig. 5a).
The G protein was present in cells infected with wt rA2,
Ggs, and mG (lanes 2, 3, and 6, respectively). The level of
expression of G appeared to be somewhat increased for
the latter two viruses. As expected, expression of the G
protein was not observed for the DG virus (Fig. 5a, lane
4), and cell-associated G protein was not detectable in
cells infected with sG (Fig. 5a, lane 5). Western blot
analysis with an antiserum specific for a peptide con-
taining amino acids 186–201 of G confirmed that G pro-
ses. HEp-2 (a–f) or Vero (g–l) cells were left uninfected (a, g) or were
ated for 4 days under methyl cellulose. Photomicrographs were takennt virutein was not detectable in cells infected with DG or sG
(Fig. 5b, lanes 4 and 5, respectively). The lack of cell-
(
4
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288 TENG, WHITEHEAD, AND COLLINSassociated sG implied that its secretion was rapid and
efficient.
We next investigated the accumulation of G protein in
the medium overlying infected cells. Vero cells were
infected with the various mutants, incubated for 16.75 h,
and radiolabeled by incubation for a further 6 h with a
mixture of [35S]methionine and [35S]cysteine. The medium
supernatants were collected, clarified by centrifugation,
and analyzed by immunoprecipitation (in the presence of
detergent, to disrupt released virions) using a polyclonal
antiserum against purified RSV or the G-specific mono-
clonal antibody L9 (Walsh et al., 1998). Under these
conditions, the polyclonal antiserum precipitated primar-
ily the nonglycosylated virion structural proteins, and G
was present as a faint and diffuse band that was barely
discernible (Fig. 5c), presumably due to the low methio-
nine content of the protein and inefficient precipitation by
the poly-specific serum. Immunoprecipitation with the
G-specific monoclonal antibody was more effective, pro-
viding unambiguous detection of released G protein (Fig.
5d). Under these conditions, G was present in the me-
dium primarily as the shorter, secreted form, consistent
with previous observations that this is the predominant
released species (Hendricks et al., 1988). Compared to
wt rA2, the Ggs virus produced a larger amount of se-
creted G (Fig. 5d, lane 2 vs 3), presumably due to the
overall increase in G expression by that mutant as
shown above. Secreted G protein was not detected with
FIG. 4. RSV RNA expression by G mutant rRSVs. Vero cells were
mock-infected (lane 1) or infected with biologically derived wt RSV (A2
wt, lane 2), rA2 (lane 3), DG (lane 4), sG (lane 5), mG (lane 6), or Ggs
lane 7) at an m.o.i. of 3 PFU/cell. Total intracellular RNA was isolated
8 h postinfection and subjected to Northern blot analysis as described
reviously (Teng and Collins, 1999) using a 32P-labeled negative-sense
riboprobe for the G gene (a) or, as a control, for the N gene (b).
Monocistronic (N and G) and readthrough (N-P and NS2-N) RNAs are
indicated at right.the DG virus (Fig. 5d, lane 4), as would be expected. The
sG virus efficiently expressed secreted G protein (Fig. 5d,lane 5), whereas secreted G was not detected for mG
(lane 6).
The results in Figs. 4 and 5 indicated that the intro-
duced mutations had the following effects: sG produced
only secreted G, mG produced only membrane-bound G,
DG did not produce either form, and Ggs produced both
forms in a fashion resembling wt RSV except that the
overall quantity was increased due to elimination of the
upstream AUG. The finding that ablation of the upstream
FIG. 5. Comparison of the amount of cell-associated (a and b) and
released (c and d) viral proteins expressed by RSV G mutants. Western
blot analysis of cell-associated proteins (a and b): Vero cells were
mock-infected (lane 1) or infected with wt rA2 (lane 2), Ggs (lane 3), DG
(lane 4), sG (lane 5), or mG (lane 6) at an m.o.i. of 3 PFU/cell. At 48 h
postinfection, the cell monolayer was harvested and subjected to
Western blot analysis using antiserum against whole virus (a) or
against a peptide representing amino acids 186–201 of the G protein
(b). Radioimmunoprecipitation analysis of released viral proteins (c and
d): additional monolayers were infected in the same way and were
labeled by incubation with [35S]methionine and [35S]cysteine between
16.75 and 22.75 h postinfection. The medium supernatants were har-
vested, clarified, and subjected to immunoprecipitation (in the pres-
ence of detergent, to disrupt released virus) with antiserum
against whole virus (c) or with monoclonal antibody L9 specific to the
G protein (d).
erum a
289RSV G MUTANT VIRUSESAUG in Ggs increased the expression of G ORF indicates
that this structural feature of the mRNA indeed down-
regulates translation of the G ORF. However, as noted
above (Fig. 2), this was not associated with a change in
growth in vitro and hence appears to be relatively inci-
dental and the Ggs virus was not investigated further.
Inefficient initiation of infection by the DG virus in
HEp-2 cells
As described above, the DG virus replicated as effi-
ciently as wt RSV in Vero cells but was 103- or 104-fold
less efficient in HEp-2 cells. It seemed likely that the
defect in HEp-2 cells would be at the level of attachment
and entry. To investigate this directly, HEp-2 cells and
Vero cells were infected in parallel with Vero-grown DG
virus and various control viruses at an m.o.i. of 1 PFU/
cell, incubated for 16 h to allow protein synthesis to
proceed, and analyzed by indirect immunofluorescence
with a polyclonal antiserum directed against the N pro-
tein followed by a FITC-coupled secondary antibody. As
shown in Fig. 6, DG appeared to infect Vero cells (panel
h) with an efficiency comparable to that of rA2 (panel g)
or mG (panel j), whereas in HEp-2 cells there were very
few infected cells with DG (panel c) compared to rA2
(panel b) and mG (panel e). Interestingly, the efficiency of
sG infection did not appear to differ between the two cell
lines (Fig. 6d vs Fig. 6i), suggesting that this virus had no
defect in its attachment function. Thus, the DG virus was
defective for initiating infection in HEp-2 cells.
Expression and release of viral proteins from infected
cells
FIG. 6. Comparison of the efficiency of infection of HEp-2 and Vero ce
on coverslips and left uninfected (a, f) or were infected at an m.o.i.
immunofluorescence analysis 16 postinfection using a polyclonal antis
203.We next examined whether there were differences in
the ability of the G mutant viruses to produce virions inthe two different cell lines, since a defect at this stage
could also contribute to the difference in the efficiency of
growth of the DG virus. Therefore, we compared the
amount of cell-associated protein synthesized by the G
mutant viruses, which would be an indication of the
efficiency of infection, with the amount of released viral
protein, which would be an indication of the efficiency of
virion production. Cells were infected with an m.o.i. of 3
PFU/cell, incubated for 16.75 h, radiolabeled for 8 h, and
subjected to a 4-h postlabeling chase incubation. The
cells and medium supernatants were processed in par-
allel by immunoprecipitation with polyclonal antibodies
raised against RSV virions, followed by gel electrophore-
sis. The amount of cell-associated (Fig. 7a) and released
(Fig. 7b) viral protein was quantified and normalized
relative to that of the wt rA2 virus (Fig. 7c).
All of the G mutant viruses infected Vero cells with an
efficiency similar to that of the wt rA2 based on the
accumulation of cell-associated protein (Fig. 7a, lanes
6–10). In Vero cells, infection by the rA2, DG, and sG
viruses released similar amounts of viral proteins into
the medium (Fig. 7b, lanes 6–9). The mG-infected cells
appeared to release approximately 50% less viral protein
than wt rA2 (Fig. 7c), though this difference was less
pronounced in independent experiments (data not
shown). In HEp-2 cells, wt rA2 and mG appeared to infect
and release viral proteins to similar levels (Figs. 7a and
7b, lanes 2 and 5). Infection of HEp-2 cells by sG ap-
peared to lead to slightly less cell-associated viral pro-
tein (Fig. 7a, lane 4) and correspondingly less viral pro-
tein in the supernatant (Fig. 7b, lane 4). In addition, DG
infection of HEp-2 cells resulted in markedly less protein
t rA2 and G mutant viruses. HEp-2 (a–e) and Vero (f–j) cells were grown
th rA2 (b, g), DG (c, h), sG (d, i), or mG (e, j) and then subjected to
gainst RSV N and a FITC-coupled secondary antibody. Magnification,lls by w
of 1 wiin both the cell extract and the supernatant (Figs. 7a and
7b, lane 3) to levels approximately 10-fold lower than rA2
v
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290 TENG, WHITEHEAD, AND COLLINS(Fig. 7c). For both DG and sG, the relative amount of
released protein was lower than the relative amount of
cell-associated protein, indicative of a small reduction in
the efficiency of virion production. Thus, the reduced
efficiency of growth of the DG virus in HEp-2 cells was
primarily at the level of initiation of infection, presumably
absorption and penetration, with a minor additional com-
ponent at the level of virion morphogenesis.
Infection of Vero cells with DG and sG is insensitive
to soluble GAGs
FIG. 7. Comparison of the amount of cell-associated and released
viral proteins from cells infected by G mutant rRSVs. HEp-2 (lanes 1–5)
or Vero (lanes 6–10) cells were uninfected (lanes 1 and 6) or infected by
rA2 (lanes 2 and 7), DG (lanes 3 and 8), sG (lanes 4 and 9), or mG (lanes
5 and 10). At 12.75 h postinfection, cells were labeled with [35S]methi-
onine and [35S]cysteine for 8 h followed by a 4-h chase. Viral proteins
rom cell extracts (CE, a) or supernatants (Sup, b) were immunopre-
ipitated using antiserum against whole virus. (c) Densitometric anal-
sis of autoradiographs shown in (a) and (b). Densitometry was per-
ormed on bands corresponding to P and M from each lane and the
um was compared to that of rA2. Background levels for each band
rom uninfected cells were subtracted from each total. A representative
f three experiments is shown.We examined the ability of soluble GAGs to block
infection of HEp-2 and Vero cells by the G mutant rRSVs
a
cin a plaque reduction assay. The virus was incubated
with varying dilutions of soluble GAG for 15 min and
allowed to adsorb to the cell monolayer for 1 h. The
inoculum was then removed, and the cells were washed
once with PBS and incubated under methyl cellulose in
the absence of GAG. Thus, the assay measured solely
effects on the initial absorption. Wt rA2, sG, and mG were
all very sensitive to heparin in HEp-2 cells (Fig. 8a,
closed symbols); since DG did not form plaques in HEp-2
cells, its heparin sensitivity could not be assessed in this
cell line. As a control, we also examined three clinical
nasal wash samples containing RSV, one of which was
identified as being from subgroup A and the others from
subgroup B based on reactivity with diagnostic monoclo-
nal antibodies. These were direct nasal wash samples
from naturally acquired RSV infections and had not been
passaged in vitro. All three viruses were equivalent to
the laboratory rA2 strain in sensitivity to neutralization
with heparin (M. N. Teng, R. A. Karron, and P. L.
Collins, unpublished data), showing that this property is
shared by RSV isolates that have never been passaged
in vitro.
Wt rA2, sG, and mG also were neutralized on HEp-2
cells by soluble preparations of heparan sulfate and
chondroitin sulfate B, but not chondroitin sulfate A or C,
although an approximately 5- to 10-fold higher concen-
tration of each GAG compared to heparin was necessary
for a comparable magnitude of effect (data not shown). In
Vero cells, the percent inhibition of rA2 and mG was
somewhat less than that seen in HEp-2 cells, but both
viruses were sensitive to heparin (Fig. 8b) as well as to
heparan sulfate and chondroitin sulfate B (data not
shown). Interestingly, neither DG nor sG was sensitive to
heparin, heparan sulfate, or chondroitin sulfate B in Vero
cells (Fig. 8b and data not shown). The finding that
infection of Vero cells with DG and sG was insensitive to
soluble GAGs suggested the existence of an entry path-
way that did not involve GAGs or G.
We also tested the ability of the DG virus to infect
Chinese hamster ovary (CHO) mutant cell lines that are
deficient in the synthesis of GAGs (not shown). The pgs
A-745 cell line, which has a 15-fold reduction in xylosyl
transferase and a comparable reduction in GAG synthe-
sis and accumulation (Esko et al., 1985), was infected by
wt rA2 at an efficiency of 20–30% compared to its wt CHO
parent (Hallak et al., 2000a and our unpublished obser-
ations). In comparison, the DG virus infected the wt
HO parent and the pgs A-745 GAG-deficient mutant
ith equal efficiency, and this efficiency was the same as
t rA2 in the pgs A-745 cell line (not shown). These
esults also supported the idea of an alternate entry
athway for RSV that was independent of both G protein
nd cell surface GAGs, with the caveat that the pgs A-745
ells are not completely devoid of GAGs.
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RSV attachment or sensitivity to soluble GAGs
Since the G protein appeared to have a single pre-
dominant binding site for heparin, namely the abovemen-
tioned HBD involving amino acids 184–198 (Feldman et
al., 1999), we were interested in whether it would be
possible to recover virus lacking this domain and, if so,
how that virus would behave in vitro and in vivo. As
shown in Fig. 1b, mutant G HBD-wt was constructed by
deleting amino acids 187–197. A second version, called
G HBD-mut, was made in which the three threonine
residues at positions 198, 199, and 200 were also
changed to alanines to avoid the possible complication
of O-glycosylation immediately adjacent to the cystine
noose.
The G HBD-wt and G HBD-mut viruses were both
readily recovered. Neither virus showed a difference
relative to rA2 in the ability to form plaques and syncytia
in HEp-2 or Vero cells (Table 1 and data not shown) and
each grew with similar kinetics and similar final yield to
rA2 in each cell line (data not shown). Western blot
analysis of infected cell extracts using a rabbit antiserum
raised against purified virus indicated that the overall
pattern of accumulation of intracellular proteins by each
of the HBD mutants in Vero and HEp-2 cells was com-
parable to that of wt rA2 (Fig. 9a). An antiserum directed
against a peptide spanning amino acids 186–201 of the
G protein did not react with G protein expressed by the
HBD-mutant viruses (Fig. 9b), consistent with the nature
of the engineered deletion. However, the G protein was
detected in each case using an antiserum specific to the
N-terminus of the G protein (not shown).
We next determined whether the G HBD-mutants were
sensitive to neutralization by soluble heparin. In HEp-2
FIG. 8. Sensitivity of rRSV G mutants to neutralization by incubation w
oncentrations of heparin and were titered on HEp-2 (left) or Vero (righ
laques compared to control wells containing no heparin, and the mea
not form plaques on HEp-2 cells and thus titers could not be determincells, both G HBD-viruses were approximately as sensi-
tive to heparin as rA2 (Fig. 8a, open symbols comparedto closed squares). In addition, both HBD viruses were
sensitive to heparin in Vero cells to approximately the
same level as mG and rA2 (Fig. 8b).
uble heparin. Viruses were diluted in medium containing the indicated
s (Materials and Methods). Results are expressed as a percentage of
wo independent experiments are shown. Note that the DG virus does
that cell line.
FIG. 9. RSV protein expression by G rRSVs lacking the HBD, con-
firming the absence of the HBD in the expressed G protein. HEp-2
(lanes 1–4) or Vero (lanes 6–9) cells were mock-infected (lanes 1, 6) or
infected at an m.o.i. of 3 PFU/cell with rA2 (lanes 2, 7), G HBD-wt (lanes
3, 8), or G HBD-mut (lanes 4, 9). At 48 h postinfection, the cells were
harvested and total cellular extracts were subjected to Western blot
analysis with rabbit antiserum against (a) purified RSV or (b) a peptide
of G spanning amino acids 186–201, which would be largely absent in
the HBD mutants, since the G HBD-wt mutant lacked amino acidsith sol
t ) cell187–197, and the G HBD-mut mutant contained in addition substitutions
at amino acids 198–200.
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292 TENG, WHITEHEAD, AND COLLINSReplication of G mutant rRSV in the respiratory tract
of mice
To compare the ability of the various G mutant viruses
to infect and replicate in the respiratory tract of mice,
groups of BALB/c mice were infected intranasally with
106 PFU of virus per animal. Four days later the animals
ere sacrificed and nasal turbinates and lungs were
arvested and virus titers determined by plaque assay
Table 2).
The DG virus was found to be highly attenuated in vivo,
ith no detectable virus in the upper respiratory tract and
very low level of virus (at the limit of detection for our
ssay) in the lower respiratory tract of 60% of the ani-
als. The mG virus appeared to be marginally reduced
0.6 log10) in replication in the upper respiratory tract, but
this likely reflected experimental variability. Somewhat
surprisingly, replication of the sG virus was only moder-
ately reduced in the upper and lower respiratory tract (1.7
log10 and 0.9 log10 reduction, respectively) compared to
the wt control. Similarly, the G HBD-wt virus replicated
nearly as efficiently as the wt control (1.0 log10 and 0.5
log10 reduction in the upper and lower respiratory tract,
respectively), while the G HBD-mut derivative was further
reduced, presumably due to the three amino acid sub-
stitutions that had been introduced next to the deletion
point.
DISCUSSION
We have recovered rRSV in which the G gene was
modified or deleted altogether. Interestingly, the DG virus
replicated and formed syncytia and plaques in Vero cells
as efficiently as wt RSV. In contrast, the DG virus was
greatly reduced in replication and did not form distinct
plaques in HEp-2 cells. The DG virus also was highly
T
Growth of G Mutant rRSV in the Upper a
Virusa
Nasal turbinatesb
% Shedding
Mean titer 6 SEM
(log10 PFU/g tissue)
Red
me
(log
rA2 100 4.2 6 0.15
DG 0 ,2.0
G 100 2.5 6 0.22
mG 100 3.6 6 0.09
G HBD-wt 100 3.2 6 0.10
G HBD-mut 60 2.0 6 0.08
a BALB/c mice in groups of five were administered 106 PFU of the in
b Animals were sacrificed on day 4. Nasal turbinates and lungs were
of detection for virus in the upper and lower respiratory tracts was 2.0
c Reduction of mean titer compared to wt rA2.restricted for replication in the respiratory tract of mice.
Thus, the G protein has characteristics of a nonessential
a
raccessory protein and is either completely dispensable
(Vero cells) or increases the efficiency of infection (HEp-2
cells, mice). In addition, the size of syncytia induced by
the various mutants in HEp-2 cells corresponded to the
level of accumulation of cell-associated G, whereas this
association was inconsistent in Vero cells. Taken to-
gether, this provides a useful system for structure-func-
tion studies of the G protein in infectious rRSV: G mutant
viruses can be propagated in Vero cells, where G func-
tion appears to be irrelevant, and then assayed in HEp-2
cells or mice, where G function is important.
The finding that the DG virus was viable in vitro was
ot completely unexpected, given the previous isolation
f the biologically derived RSV B subgroup vaccine can-
idate cp-52, which had sustained a deletion of most of
he SH and G genes (Karron et al., 1997). That G is not
ssential for packaging and passage also had been
uggested from results with an in vitro packing system
ased on plasmid-supplied minigenome and proteins
Teng and Collins, 1998): in that system, inclusion of G
as not essential but increased the efficiency of pas-
age 10-fold. The present study provided the opportunity
or evaluation of the effect of deleting G in the back-
round of an otherwise wt infectious virus. In contrast,
p-52 has the cold-adaptation and attenuation pheno-
ypes, lacks the SH gene, contains an aberrant 91-nucle-
tide SH-G fusion gene relict, and has seven other nu-
leotide changes including five amino acid coding
hanges in F and L. In addition, the recombinant system
ermitted us to analyze the effects of mutations involving
ther features of the G gene and protein.
When the DG virus was inoculated into the respiratory
ract of mice, virus was not recovered 4 days later from
he upper respiratory tract, whereas a very low titer was
ecovered from the lower respiratory tract of 60% of the
wer Respiratory Tracts of BALB/c Mice
Lungsb
of
c
g) % Shedding
Mean titer 6 SEM
(log10 PFU/g tissue)
Reduction of
mean titerc
(log10 PFU/g)
100 4.6 6 0.06 —
60 1.7 6 0.07 2.9
100 3.7 6 0.10 0.9
100 4.9 6 0.12 —
100 4.1 6 0.15 0.5
100 3.8 6 0.09 0.8
d virus intranasally under light anesthesia on day 0.
ted and virus titers were determined by plaque assay. The lower limit
.7 log10 PFU/g, respectively.ABLE 2
nd Lo
uction
an titer
10 PFU/
—
.2.2
1.7
0.6
1.0
2.2
dicate
harvesnimals. It is likely that this represents a very low level of
eplication, but it was not possible to exclude the possi-
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293RSV G MUTANT VIRUSESbility that the recovered virus represented carryover from
the inoculation. In any event, this shows that G is essen-
tial for significant replication in vivo. The cp-52 vaccine
candidate was previously shown to be overattenuated in
susceptible humans and thus is not suitable as a live-
attenuated vaccine (Karron et al., 1997). The finding in the
present study that deletion of the G gene alone from a wt
virus was highly attenuating for replication in mice indi-
cates that the overattenuated nature of cp-52 in vivo is
due primarily to the G deletion.
While DG infected Vero cells with an efficiency similar
to that of wt rA2, it was able to infect HEp-2 cells only
very poorly, resulting in approximately a 10-fold reduction
in levels of viral protein produced. This value is reminis-
cent of the results of our plasmid-based reconstitution
system described above, which was performed in HEp-2
cells. Immunofluorescence of infected monolayers re-
vealed a corresponding decrease in the number of
HEp-2 cells infected by DG, whereas the efficiency of
infection of Vero cells was comparable to that of wt rA2.
Analysis of viral protein released from infected cells
provided evidence of a further, small reduction in the
efficiency of the release of viral protein from HEp-2 cells
infected with sG or DG, indicating that each virus had a
mall impairment in virion morphogenesis compared to
t rA2. Thus, the low level of infectious virus production
y DG-infected HEp-2 cells appears to be due primarily
o a low efficiency of infection, with a minor secondary
ffect at the level of virion morphogenesis. Some viral
lycoproteins play a central role in the assembly and
udding of enveloped viruses (Cathomen et al., 1998;
ouillot-Coriou and Roux, 2000; Teng and Collins, 1998;
hang et al., 2000). In contrast, RSV G does not appear to
e necessary for budding in Vero or HEp-2 cells.
One unexpected observation is that the secreted form
f G appeared to be fully sufficient to allow efficient
eplication of RSV in HEp-2 cells. In addition, when eval-
ated for replication in mice, the sG virus was interme-
iate in efficiency between wt rA2 and the DG virus,
indicating that the secreted form also can provide much
of the function of G in vivo. Thus, the ectodomain is
largely sufficient to provide G function under conditions
where it is necessary. Furthermore, we confirmed that
the G protein produced by the sG virus was efficiently
secreted into the medium and did not remain detectably
cell-associated. One possibility is that the necessary G
function can be provided by the soluble ectodomain,
although we have not been able to “rescue” the growth of
DG in HEp-2 cells by supplying medium containing se-
creted G (unpublished data). Another possibility is that
sufficient secreted G remains associated with virions to
mediate attachment in HEp-2 cells and in mice.
This study, together with the previous analysis of cp-52
(Karron et al., 1997), showed that the G protein is not theole attachment activity. The previous identification of G
s the primary attachment protein was based on the
l
abservation that G-specific antiserum reduced the ab-
orption of radiolabeled virus, whereas F-specific anti-
erum did not (Levine et al., 1987). However, the level of
nhibition was only 50–70%; thus, these prior data do not
reclude an alternative attachment activity. Since F is the
nly surface protein in common between cp-52 and DG,
t is the likely candidate. This is somewhat reminiscent of
he situation with Sendai virus, where the major attach-
ent HN protein can be dispensable for budding in vitro,
nd virus absorption and penetration can be mediated by
he F protein via the asialoglycoprotein receptor (Fouillot-
oriou and Roux, 2000; Leyrer et al., 1998). Recently, the
RSV F protein was shown to bind RhoA, a small GTPase
involved in cytoskeletal rearrangement (Pastey et al.,
1999). Whether or not this interaction is involved in F-
mediated attachment is unclear.
Several laboratories have provided evidence that effi-
cient RSV infection in vitro requires cell surface GAGs,
notably heparan sulfate and chondroitin sulfate B (Feld-
man et al., 1999; Hallak et al., 2000a,b; Krusat and Streck-
rt, 1997). Both the G and F glycoproteins have been
hown to bind to immobilized GAG. Furthermore, efficient
nfection by the cp-52 mutant, bearing only the F protein,
ppeared to require cell surface GAGs (Feldman et al.,
000). These observations suggest that both G-mediated
nd putative F-mediated attachment involve GAGs. In the
resent study, we found that infection of HEp-2 cells by
t rA2 or by the various G mutant RSVs was highly
ensitive to neutralization by soluble heparin, heparan
ulfate, and chondroitin sulfate B, although the DG virus
ould not be evaluated in this cell line because it did not
orm distinct plaques regardless of the absence or pres-
nce of heparin. We also found that virus in clinical
pecimens representing both antigenic subgroups could
e neutralized by heparin with the same sensitivity as the
t laboratory A2 strain, indicating that GAG-binding is an
uthentic property of RSV rather than an artifactual one
cquired during passage in vitro.
In Vero cells, the wt and mG viruses also were sensi-
ive to inhibition by soluble GAGs; however, the DG and
G viruses were not. This finding suggests that there is
n alternative entry pathway in Vero cells that is inde-
endent of G and does not involve these GAGs. It is
nteresting that wt rA2, mG, Ggs, and the HBD mutants
emained sensitive to neutralization by GAGs in Vero
ells. It might be that the binding of these large, charged
olecules to virion G protein blocked the putative alter-
ative entry pathway by a nonspecific effect such as
harge or steric hindrance. Thus, our results, together
ith work by others (Feldman et al., 2000; Karron et al.,
997), provide evidence that both G and F can mediate
ttachment. However, the present paper suggests that
here is an entry pathway that is independent both of G
nd of GAGs, at least in Vero cells, which differs in theatter regard from the findings of Feldman et al. (2000). In
ddition, it is clear that the putative HBD described for
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294 TENG, WHITEHEAD, AND COLLINSthe G protein is not of major importance for infection in
vitro or in vivo and that ablation of this domain did not
alter the sensitivity of RSV to neutralization by soluble
GAGs. Thus, the GAG-binding domains of G remain to be
determined.
The G protein is one of the two major RSV protective
antigens, together with the F protein. However, some
evidence suggests that G-specific immunity might also
include a pathogenic component. In the BALB/c mouse
model, immunization with a vaccinia virus recombinant
expressing the G protein primed for the development of
lung eosinophilia upon RSV challenge, and this effect
was enhanced when the secreted form of G was ex-
pressed alone (Johnson and Graham, 1999; Johnson et
al., 1998). The availability of the sG and mG viruses, and
in particular the finding that the sG virus replicates effi-
ciently in vivo, will make it possible to investigate
whether there are important differences in the host im-
mune response to viruses bearing the various forms and
whether a recombinant RSV vaccine virus should be
engineered to ablate the secreted form.
MATERIALS AND METHODS
Plasmid construction
We previously constructed a cDNA clone encoding the
antigenomic RNA of RSV strain A2 (antigenic subgroup
A) under the control of a T7 promoter (Collins et al., 1995).
To mutate the G gene, a pUC19 plasmid containing the G,
F, and M2 genes bordered by naturally occurring PacI
and BamHI sites (pUC19-GFM2) was subjected to PCR
with Vent DNA polymerase (New England Biolabs) using
the method of Byrappa et al. (1995). Oligonucleotides
were designed such that they would prime the GFM2
plasmid in opposite directions to produce a linear plas-
mid incorporating the desired mutations. The 59-phos-
phorylated oligonucleotides used were as follows (note
that each is named according to the resulting G mutant
(see Fig. 1) and numbered according to the complete
15,223-nt recombinant antigenome sequence; nucleotide
changes are shown in lowercase; italics denote a novel
MfeI site, underlining indicates discontinuous sequence
that spans a deletion site):
DG forward: 59 CCTTGACCAACTTAAACAGAATC 39
(5614–5635)
DG reverse: 59 CCTGTCTTGATATCCTAGTTCATTGTT-
ATG 39 (5613–5611, underlined; 4659–4633)
sG forward: 59 AAACATGATAATCTCAACTTCAC 39
(4685–4688, underlined; 4830–4848)
sG reverse: 59 GCATTTGCCCCAATGTTATTG 39 (4684–
664)Ggs forward: 59 AAACATGTCCAAAAACAAGGACC 39
4685–4707)Ggs reverse: 59 GgATTTGCCCCAATGTTATTG 39
(4684–4664)
mG forward: 59 TTATAATTGCAGCCATCATATTCATAGC-
CTCGG 39 (4849–4881)
mG reverse: 59 GTGAAGTTGAGATTACAATTGCCA-
GAATGG 39 (4848–4819)
HBD-wt forward: 59 ACCACTACCAAGCCCACAAAA-
AAACCAACCCTC 39 (5280–5312)
HBD-mut forward: 59 gCCgCTgCCAAGCCCACAAA-
AAAACCAACCCTC 39 (5280–5312)
HBD-reverse: 59 TTTGCAGATAGCCCAGCAGGTTG-
GATTGTTGCTGC 39 (5249–5215)
The PCR products were isolated by agarose gel electro-
phoresis, self-ligated, and transformed into DH10B com-
petent cells (Life Technologies). The presence of the
mutations was confirmed by restriction digest and nu-
cleotide sequencing between the PacI and StuI sites.
he mutated (or deleted) G ORFs were excised from the
FM2 plasmids using PacI and StuI and replaced into
FM2. The PacI–BamHI fragment of these mutated
FM2 plasmids were inserted into the PacI–BamHI win-
ow of D51, reconstructing the previously described D50
lasmid that contains the antigenomic cDNA from the
eader region to the end of the M2 gene (Teng and
ollins, 1999). Full-length antigenomic cDNAs were then
ssembled by inserting the BamHI–MluI fragment of D39
ites (Collins et al., 1995; Juhasz et al., 1997) into the
mutant D50 plasmids. The G mutant viruses used in all of
the in vitro experiments were constructed with a version
of antigenomic cDNA (Collins et al., 1995) containing two
previously described modifications (Teng and Collins,
1999; Whitehead et al., 1998): namely (i) a series of
translationally silent nucleotide changes in the L gene
that introduce restriction sites, and (ii) two amino acid
substitutions in the F protein that make the virus identical
at the amino acid level to the HEK isolate of RSV strain
A2 that served as the progenitor for a panel of vaccine
candidates currently in clinical trials. In previous work,
these changes did not affect virus replication in vitro or in
chimpanzees. However, we subsequently found that the
two HEK amino acid substitutions have a species-spe-
cific attenuating effect in BALB/c mice (S. S. Whitehead,
P. L. Collins, and B. R. Murphy, unpublished data). There-
fore, for the purpose of the mouse study, the viruses were
remade in the original backbone (Collins et al., 1995)
lacking the HEK substitutions.
Western blot analysis
Cell pellets from infected cells were disrupted by ad-
dition of 23 sample buffer (100 mM Tris–Cl pH 6.8, 4%
SDS, 20% glycerol, 0.2% bromphenol blue, 200 mM DTT)
and centrifugation through Qiashredders (Qiagen). Ap-
proximately 1.5 3 105 cell equivalents of each infected
cell extract were subjected to electrophoresis on 4–20%
SDS–polyacrylamide gels (Novex) and transferred to
BB
C
C
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295RSV G MUTANT VIRUSESPVDF membrane (Novex). Blots were incubated with
rabbit antiserum raised against either purified RSV (Teng
and Collins, 1999), a peptide containing the N-terminal 12
amino acids of the G protein (Collins and Mottet, 1992),
or a peptide spanning amino acids 186–201 of the G
protein. Viral proteins were visualized by secondary in-
cubation with horseradish peroxidase-coupled goat anti-
rabbit IgG antibodies followed by chemiluminescence
(Amersham).
Radioimmunoprecipitation assay
Radioimmunoprecipitation was performed essentially
as described (Collins and Mottet, 1992). Briefly, HEp-2 or
Vero cell monolayers in six-well clusters were infected
for 1 h at 37°C with the indicated viruses at an m.o.i. of
3 PFU/cell. Twelve (Fig. 7) or 16 (Fig. 5) h postinfection,
the medium was removed and the infected cells were
incubated with methionine-free medium for 45 min. The
cells were subsequently labeled with Tran35S-label (Am-
ersham) for 6 (Fig. 5) or 8 (Fig. 7) h. For the experiment in
Fig. 7, the labeling was followed by a 4-h chase. Super-
natants were harvested and clarified by low-speed cen-
trifugation; cellular extracts were made by lysing the cell
pellets in RIPA buffer followed by centrifugation to pellet
the nuclei. Clarified supernatants and cell extracts were
then incubated overnight with either monoclonal anti-G
antibody (L9) or polyclonal anti-RSV rabbit antiserum.
Proteins were precipitated using protein A–agarose
(Pharmacia) and separated by SDS–PAGE on 4–20% gels
(Novex).
Immunofluorescence assay
HEp-2 or Vero cells were grown on 10-mm coverslips
and infected with the indicated rRSV at an m.o.i. of 1
PFU/cell. At 16 h postinfection, the cells were fixed with
methanol/acetone (1:1). The expression of RSV protein
was detected with a rabbit antiserum that had been
generated against baculovirus-expressed bovine RSV N
protein and reacts strongly with the N protein of human
RSV, a kind gift of Dr. Siba Samal. The coverslips were
incubated in a 1:100 dilution of this antiserum for 1 h
followed by goat anti-rabbit Ig antibody coupled to FITC
(1:100). Coverslips were mounted on slides with Per-
mount (Fisher) and photomicrographs were taken using
a Leitz Fluovert microscope at a magnification of 403.
Neutralization of RSV infectivity with soluble GAGs
Virus dilutions containing approximately 105 PFU/ml
were preincubated in OptiMEM (Life Technologies) con-
taining the indicated concentrations of bovine lung hep-
arin (Sigma) for 15 min at room temperature and titered
on HEp-2 and Vero cells as described (Murphy et al.,
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